Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
Apr 10 - Apr 15, 2021AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) 2021 ANNUAL MEETING
Mar 9 - Mar 10, 2021H.C. WAINWRIGHT GLOBAL LIFE SCIENCES 2021 CONFERENCE
Jan 11 - Jan 14, 2021H.C. WAINWRIGHT BIOCONNECT 2021 CONFERENCE